Robert W Holloway

8PUBLICATIONS
45CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 28, 2025
A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer.

Robert W Holloway, Sarah M Temkin, Sarah W Gordon

|Sep 24, 2025
Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer.

Peter W Ketch, Carly Bess Scalise, Fernando Recio

|Jul 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian

|Jun 03, 2024
Neoadjuvant chemotherapy with bevacizumab for locally advanced vulvar cancer.

Theresa M Kuhn, Sarfraz Ahmad, Fernando O Recio

|Oct 31, 2023
Standardized Titration Protocol Reduces the Incidence of Paclitaxel Infusion-Related Hypersensitivity Reactions.

Kofi Sefah, Karolina A Kilowski, Sarah A Gifford

|Sep 04, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.

Robert W Holloway, Premal Thaker, Alberto A Mendivil

Pageof 2

Frequent Collaborators

5 joint publications

Sarfraz Ahmad

2 joint publications

Bradley J Monk

1 joint publications

Peter W Ketch

1 joint publications

Fernando Recio